# A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

> **NCT00921869** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** E7050

## Key facts

- **NCT ID:** NCT00921869
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00921869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00921869, "A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00921869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*